IBDEI0JW ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8772,1,4,0)
 ;;=4^I20.0
 ;;^UTILITY(U,$J,358.3,8772,2)
 ;;=^5007076
 ;;^UTILITY(U,$J,358.3,8773,0)
 ;;=I20.9^^69^599^1
 ;;^UTILITY(U,$J,358.3,8773,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8773,1,3,0)
 ;;=3^Angina Pectoris,Unspec
 ;;^UTILITY(U,$J,358.3,8773,1,4,0)
 ;;=4^I20.9
 ;;^UTILITY(U,$J,358.3,8773,2)
 ;;=^5007079
 ;;^UTILITY(U,$J,358.3,8774,0)
 ;;=I31.9^^69^599^16
 ;;^UTILITY(U,$J,358.3,8774,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8774,1,3,0)
 ;;=3^Pericardium Disease,Unspec
 ;;^UTILITY(U,$J,358.3,8774,1,4,0)
 ;;=4^I31.9
 ;;^UTILITY(U,$J,358.3,8774,2)
 ;;=^5007165
 ;;^UTILITY(U,$J,358.3,8775,0)
 ;;=I49.9^^69^599^2
 ;;^UTILITY(U,$J,358.3,8775,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8775,1,3,0)
 ;;=3^Arrhythmia,Cardiac,Unspec
 ;;^UTILITY(U,$J,358.3,8775,1,4,0)
 ;;=4^I49.9
 ;;^UTILITY(U,$J,358.3,8775,2)
 ;;=^5007237
 ;;^UTILITY(U,$J,358.3,8776,0)
 ;;=I13.0^^69^599^9
 ;;^UTILITY(U,$J,358.3,8776,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8776,1,3,0)
 ;;=3^HTN Hrt Disease w/ Hrt Failure and CKD,Stage 1-4
 ;;^UTILITY(U,$J,358.3,8776,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,8776,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,8777,0)
 ;;=I13.2^^69^599^10
 ;;^UTILITY(U,$J,358.3,8777,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8777,1,3,0)
 ;;=3^HTN Hrt Disease w/ Hrt Failure and CKD, Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,8777,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,8777,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,8778,0)
 ;;=I13.10^^69^599^11
 ;;^UTILITY(U,$J,358.3,8778,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8778,1,3,0)
 ;;=3^HTN Hrt Disease w/o Hrt Failure and CKD, Stage 1-4
 ;;^UTILITY(U,$J,358.3,8778,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,8778,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,8779,0)
 ;;=I13.11^^69^599^12
 ;;^UTILITY(U,$J,358.3,8779,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8779,1,3,0)
 ;;=3^HTN Hrt Disease w/o Hrt Failure and CKD,Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,8779,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,8779,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,8780,0)
 ;;=I50.1^^69^599^15
 ;;^UTILITY(U,$J,358.3,8780,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8780,1,3,0)
 ;;=3^Left Ventricular Failure
 ;;^UTILITY(U,$J,358.3,8780,1,4,0)
 ;;=4^I50.1
 ;;^UTILITY(U,$J,358.3,8780,2)
 ;;=^5007238
 ;;^UTILITY(U,$J,358.3,8781,0)
 ;;=E21.3^^69^600^17
 ;;^UTILITY(U,$J,358.3,8781,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8781,1,3,0)
 ;;=3^Hyperparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,8781,1,4,0)
 ;;=4^E21.3
 ;;^UTILITY(U,$J,358.3,8781,2)
 ;;=^331438
 ;;^UTILITY(U,$J,358.3,8782,0)
 ;;=E78.5^^69^600^16
 ;;^UTILITY(U,$J,358.3,8782,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8782,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,8782,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,8782,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,8783,0)
 ;;=M10.30^^69^600^11
 ;;^UTILITY(U,$J,358.3,8783,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8783,1,3,0)
 ;;=3^Gout d/t Renal Impairment,Unspec Site
 ;;^UTILITY(U,$J,358.3,8783,1,4,0)
 ;;=4^M10.30
 ;;^UTILITY(U,$J,358.3,8783,2)
 ;;=^5010356
 ;;^UTILITY(U,$J,358.3,8784,0)
 ;;=E66.9^^69^600^33
 ;;^UTILITY(U,$J,358.3,8784,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8784,1,3,0)
 ;;=3^Obesity,Unspec
 ;;^UTILITY(U,$J,358.3,8784,1,4,0)
 ;;=4^E66.9
 ;;^UTILITY(U,$J,358.3,8784,2)
 ;;=^5002832
 ;;^UTILITY(U,$J,358.3,8785,0)
 ;;=E66.01^^69^600^32
